Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - For the year ended June 30, revenue is expected to more than double to £4.0 million from £1.6 million reported the prior 15-month period.

Aptamer attributes its strong performance to robust results from its three business units, including contract wins and extensions. Examples include the development of Optimer binders by Aptamer Solutions, and the extension of agreements with PinotBio Inc and AstraZeneca PLC with Aptamer Therapeutics.

‘We are pleased with the pace of progress over the past six months, having seen success in expanding our current partnerships and winning new contracts, which has delivered financial performance in line with market expectations. As well as aiming to continue delivering strong revenue growth, we are making preparations to further capitalise on the clear market opportunities, new strategic collaborations and the demand for next-generation affinity ligands key to enable our future growth,’ says Chief Executive Officer Arron Tolley.

Current stock price: 96.75 pence

12-month change: down 32%

Copyright 2022 Alliance News Limited. All Rights Reserved.